Ocular Therapeutix, Inc. (OCUL) News
Filter OCUL News Items
OCUL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCUL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OCUL News From Around the Web
Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference PresentationCompany presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative ther |
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past weekIt's been a soft week for Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shares, which are down 12%. Despite this, the stock... |
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s |
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA. 43rd Annual J.P. Morgan Healthcare Conf |
Ocular Therapeutix announces over 300 subjects randomized in SOL-1Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performin |
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization |
Ocular Therapeutix™ to Participate in December Investor and Scientific ConferencesBEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December. Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date: Tuesday, December 3rd, |
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...Ocular Therapeutix Inc (OCUL) reports robust cash reserves and significant trial advancements, despite regulatory and pricing challenges. |
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesOcular Therapeutix (OCUL) delivered earnings and revenue surprises of -13.04% and 12.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Ocular Therapeutix: Q3 Earnings SnapshotBEDFORD, Mass. AP) — Ocular Therapeutix Inc. OCUL) on Thursday reported a loss of $36.5 million in its third quarter. |